What are the Significant Drifts in the Market?

• In February 2025, Nona Biosciences, a global biotechnology entered into a strategic alliance with Invetx, Inc., to establish next-generation animal health biotherapeutics using Nona's HCAb Harbour Mice platform.
• In February 2024, Rejuvenate Bio partnered with a major animal health company to evolve gene therapy for canine osteoarthritis.

What is the Developing Limitation in the Market?

The market is mainly facing issues due to the complex regulatory process, under the various agencies, including the FDA's Center for Veterinary Medicine (CVM) and the USDA's Center for Veterinary Biologics (CVB) probably regulating several products.

Regional Analysis

What Made North America Dominant in the Market in 2024?

In the monoclonal antibodies in veterinary health market, North America captured the biggest share by 44% in 2024. The wider contribution of rising pet ownership, with expanded gene editing and new therapeutic developments, is allowing more accurate and efficient monoclonal antibodies for veterinary use. The US market is emphasising R&D efforts in oncology and infectious diseases in livestock.

• In April 2025, the U.S. Food and Drug Administration (FDA) announced an innovative strategy to phase out the need for animal testing in the development of mAbs and other drugs.
  

How did the Asia Pacific Expand Notably in the Market in 2024?

In the prospective period, the Asia Pacific is anticipated to be the fastest-growing region in the monoclonal antibodies in veterinary health market. This will be mainly propelled by the increasing awareness regarding animal health and welfare, technological breakthroughs in biotech, and government initiatives are support animal health. The Fleming Fund Regional Grant, Antimicrobial Resistance and One Health in South East Asia (AMROH SEA), powered by the Asia-Pacific Centre for Animal Health at the University of Melbourne, is offering assistance to tackle AMR in animal health (terrestrial and aquatic).

Segmental Insights

By Animal Type Analysis

Why did the Dog Segment Lead the Market in 2024?

The dog segment registered dominance with a major share of the monoclonal antibodies in veterinary health market in 2024. According to many surveys, it was found that dog is a family member of the numerous homes, which is impacting the pet ownership rates. Additionally, conditional USDA approval for Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) in puppies, Zoetis's Health Canada approval of Lenivia (izenivetmab) for osteoarthritis pain, and Elanco's investment are accelerating the production of CPMA.

By Application Analysis

Why the Dermatology Segment Dominated the Market in 2024?

The dermatology segment held the largest revenue share of the market in 2024. The globe is facing a huge rise in atopic and allergic dermatitis, which is more common in pets, specifically in dogs. The market is encouraging the use of Zoetis's Cytopoint (lokivetmab) to manage atopic dermatitis in dogs, and Merck's Gilvetmab in a few kinds of cancers, like mast cell tumours and melanomas.

Although the pain segment is estimated to expand at a lucrative CAGR in the coming era. The rising cases of osteoarthritis

By End-user Analysis

How did the Veterinary Hospital Segment Dominate the Market in 2024?

The veterinary hospital segment captured a major share of the monoclonal antibodies in veterinary health market in 2024. Globally escalating focus on enhancing animal health, and the use of advanced recombinant DNA and hybridoma technology, with broader efficacy and specificity in producing monoclonal antibodies, is leveraging veterinary developments in hospitals. Also, hospitals widely foster indigenous products, physiotherapy, and highly sophisticated diagnostic solutions.

Browse More Insights of Towards Healthcare:

The monoclonal antibody market targeting asthma and COPD

The monoclonal antibody discovery platform market

The global monoclonal antibodies market

The global biologics safety testing market

The global oncology biosimilars market

What are the Key Developments in the Market?

• In October 2025, Akston introduced a clinical study at Purdue University for its Ambifect immuno-enhancing therapy, created to induce antibodies targeting PD-L1 in dogs with solid tumours.
• In June 2025, Vetigenics unveiled CHECKMATE K9, a first dual immune heckpoint inhibitor study in dogs with solid tumours.

Monoclonal Antibodies in Veterinary Health Market Key Players List

• Zoetis
• Merck & Co, Inc.
• Elanco
• Boehringer Ingelheim GmbH
• Indian Immunologicals Ltd
• Virbac

Segments Covered in the Report

By Animal Type

• Dogs
• Others

By Application

• Dermatology
• Pain
• Others
  

By End-user

• Veterinary Hospitals
• Others

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
    

Immediate Delivery Available | Buy This Premium Research @

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard:

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research

You can place an order or ask any questions, please feel free to contact us at ...

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web:

Our Trusted Data Partners

Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest